LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Home・Akcijų sąrašas・Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

42.67 -3.04

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

41.93

Max

42.69

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-14M -130M
Pardavimai	-888K 143K
Pelno marža	-90,972.727
Darbuotojai	437
EBITDA	-12M -142M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+102.36% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-02-26

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	681M 4.7B
Ankstesnė atidarymo kaina	45.71
Ankstesnė uždarymo kaina	42.67

Naujienos nuotaikos

By Acuity

61%

39%

305 / 351 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

30.39 / 33.46 Palaikymas ir pasipriešinimas

Crinetics Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-13 16:32; UTC

Uždarbis

Enbridge, TC Energy Investing in Opportunities to Tap Rising Energy Demand, Boom in Data Centers -- Update

2026-02-14 22:02; UTC

Uždarbis

Looking for Dividends? Consider Europe. -- Barrons.com

2026-02-14 09:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-02-13 21:57; UTC

Uždarbis

Stocks Rise on Softer Inflation Data, but AI Jitters Trigger Worst Week Since November -- WSJ

2026-02-13 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-02-13 21:20; UTC

Uždarbis

Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More Stock Market Movers -- Barrons.com

2026-02-13 21:05; UTC

Įsigijimai, susijungimai, perėmimai

Constellation Software: Lumine Group Completes Acquisition of Synchronoss Technologies >CSU.T SNCR

2026-02-13 20:45; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-02-13 20:45; UTC

Rinkos pokalbiai

Dollar Pares Down Early Losses -- Market Talk

2026-02-13 20:39; UTC

Rinkos pokalbiai

Potential for Mild Winter Ahead Sinks Natural Gas for Week -- Market Talk

2026-02-13 20:28; UTC

Rinkos pokalbiai

Oil Settles Week Lower -- Market Talk

2026-02-13 19:51; UTC

Uždarbis

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

2026-02-13 19:32; UTC

Rinkos pokalbiai

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

2026-02-13 19:32; UTC

Rinkos pokalbiai

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

2026-02-13 19:29; UTC

Uždarbis

Big Tech's Spending Spree Could Limit Buybacks and Dividends -- Barrons.com

2026-02-13 18:18; UTC

Įsigijimai, susijungimai, perėmimai

Exxon, Walmart and 9 Other Stocks That Are Soaring Because Cash Is King Again -- Barrons.com

2026-02-13 17:52; UTC

Uždarbis

Pinterest's Earnings Give More Proof of Meta Platform's Dominance -- Barrons.com

2026-02-13 17:16; UTC

Uždarbis

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

2026-02-13 17:10; UTC

Įsigijimai, susijungimai, perėmimai

Vibe-Coding in Gas Town? A Guide to the Software Selloff With 4 Sexy Stock Picks. -- Barrons.com

2026-02-13 16:59; UTC

Uždarbis

AppLovin Stock Stabilizes After Selloff. Its Biggest Critic Waves the White Flag. -- Barrons.com

2026-02-13 16:39; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire Might Have Sold More Apple, Bank of America Stock in Fourth Quarter -- Barrons.com

2026-02-13 16:11; UTC

Uždarbis

Nvidia Stock Wobbles. The Focus Is Turning to Earnings. -- Barrons.com

2026-02-13 16:07; UTC

Rinkos pokalbiai

Hungarian Forint Could Rise Further -- Market Talk

2026-02-13 15:54; UTC

Uždarbis

Detroit Automakers Take $50 Billion Hit as EV Bubble Bursts -- WSJ

2026-02-13 15:26; UTC

Rinkos pokalbiai

Indian Imports of Saudi Crude Hit Highest Since 2022 -- Market Talk

2026-02-13 15:01; UTC

Uždarbis

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Steel Dynamics, Coinbase, DraftKings, Tri Pointe Homes, and More -- Barrons.com

2026-02-13 15:00; UTC

Uždarbis

Expedia Falls, but Airbnb Rises. Why Online Travel Stocks Face a Tough Year. -- Barrons.com

2026-02-13 14:50; UTC

Rinkos pokalbiai

Oil Moves Lower As Market Weighs Geopolitical Risk -- Market Talk

2026-02-13 14:44; UTC

Uždarbis

Arista Networks Stock Climbs. Why It Is Outshining Cisco. -- Barrons.com

2026-02-13 14:22; UTC

Rinkos pokalbiai

Uždarbis

Global Energy Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Crinetics Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

102.36% į viršų

12 mėnesių prognozė

Vidutinis 89.2 USD 102.36%

Aukščiausias 105 USD

Žemiausias 67 USD

Remiantis 11 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Crinetics Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

11 ratings

Pirkti

Laikyti

Parduoti

Remiantis 11 analitikų, pateikusių Crinetics Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

30.39 / 33.46Palaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Rinkos nuotaikos

By Acuity

305 / 351 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.